Cibus (CBUS) Competitors $3.95 -0.02 (-0.50%) (As of 09:48 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CBUS vs. MBII, LFVN, AVD, CGA, NAII, LXFR, ARQ, SDST, SLI, and AMTXShould you be buying Cibus stock or one of its competitors? The main competitors of Cibus include Marrone Bio Innovations (MBII), LifeVantage (LFVN), American Vanguard (AVD), China Green Agriculture (CGA), Natural Alternatives International (NAII), Luxfer (LXFR), ARQ (ARQ), Stardust Power (SDST), Standard Lithium (SLI), and Aemetis (AMTX). Cibus vs. Marrone Bio Innovations LifeVantage American Vanguard China Green Agriculture Natural Alternatives International Luxfer ARQ Stardust Power Standard Lithium Aemetis Cibus (NASDAQ:CBUS) and Marrone Bio Innovations (NASDAQ:MBII) are both small-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking. Does the MarketBeat Community favor CBUS or MBII? Marrone Bio Innovations received 221 more outperform votes than Cibus when rated by MarketBeat users. However, 100.00% of users gave Cibus an outperform vote while only 47.54% of users gave Marrone Bio Innovations an outperform vote. CompanyUnderperformOutperformCibusOutperform Votes11100.00% Underperform VotesNo VotesMarrone Bio InnovationsOutperform Votes23247.54% Underperform Votes25652.46% Which has more volatility & risk, CBUS or MBII? Cibus has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Marrone Bio Innovations has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Is CBUS or MBII more profitable? Marrone Bio Innovations has a net margin of -47.07% compared to Cibus' net margin of -10,724.78%. Cibus' return on equity of -28.17% beat Marrone Bio Innovations' return on equity.Company Net Margins Return on Equity Return on Assets Cibus-10,724.78% -28.17% -13.39% Marrone Bio Innovations -47.07%-70.87%-25.23% Which has better earnings & valuation, CBUS or MBII? Marrone Bio Innovations has higher revenue and earnings than Cibus. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCibus$1.82M57.43-$267.64M-$22.48-0.18Marrone Bio Innovations$44.31M3.28-$16.55M-$0.12-6.65 Do analysts rate CBUS or MBII? Cibus currently has a consensus target price of $22.83, suggesting a potential upside of 478.06%. Given Cibus' stronger consensus rating and higher probable upside, analysts clearly believe Cibus is more favorable than Marrone Bio Innovations.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cibus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Marrone Bio Innovations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in CBUS or MBII? 33.8% of Cibus shares are held by institutional investors. Comparatively, 68.4% of Marrone Bio Innovations shares are held by institutional investors. 49.4% of Cibus shares are held by insiders. Comparatively, 5.0% of Marrone Bio Innovations shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer CBUS or MBII? In the previous week, Cibus had 9 more articles in the media than Marrone Bio Innovations. MarketBeat recorded 9 mentions for Cibus and 0 mentions for Marrone Bio Innovations. Cibus' average media sentiment score of -0.18 beat Marrone Bio Innovations' score of -0.38 indicating that Cibus is being referred to more favorably in the media. Company Overall Sentiment Cibus Neutral Marrone Bio Innovations Neutral SummaryCibus beats Marrone Bio Innovations on 13 of the 19 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Cibus News Delivered to You Automatically Sign up to receive the latest news and ratings for CBUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBUS vs. The Competition Export to ExcelMetricCibusAgricultural chemicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$104.52M$4.20B$14.57B$8.80BDividend YieldN/A3.66%2.65%4.07%P/E Ratio-0.1838.1319.5513.60Price / Sales57.435.724.4387.40Price / Cash0.567.3320.7736.27Price / Book0.971.046.136.33Net Income-$267.64M$314.10M$580.49M$225.93M7 Day Performance-17.36%-2.05%0.13%-0.96%1 Month Performance7.34%-7.84%-2.97%1.06%1 Year Performance-68.27%-31.05%10.23%26.59% Cibus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBUSCibus2.7897 of 5 stars$3.95-0.5%$22.83+478.1%-67.7%$104.52M$1.82M-0.18183MBIIMarrone Bio InnovationsN/A$0.80flatN/A+0.0%$145.56M$44.31M-6.65153LFVNLifeVantage2.9406 of 5 stars$13.08+1.2%N/A+121.0%$163.76M$200.16M40.41260AVDAmerican Vanguard4.0814 of 5 stars$6.12-1.1%$16.67+172.3%-32.9%$176.20M$579.37M0.00845Positive NewsCGAChina Green Agriculture0.5577 of 5 stars$1.90-3.0%N/A-4.4%$28.13M$95.85M-0.97424Analyst ForecastNews CoverageNAIINatural Alternatives International0.3468 of 5 stars$4.36-1.4%N/A-27.8%$27.03M$113.80M0.00290Analyst ForecastNews CoverageLXFRLuxfer3.8707 of 5 stars$14.14+0.4%N/A+65.6%$378.67M$405M42.671,400Positive NewsARQARQ2.9555 of 5 stars$7.65+1.7%$10.00+30.7%N/A$321.53M$99.18M-752.00140Analyst ForecastSDSTStardust Power2.0705 of 5 stars$6.74-2.9%$12.50+85.5%N/A$321.50MN/A0.00N/AAnalyst ForecastNews CoverageNegative NewsSLIStandard Lithium1.7678 of 5 stars$1.67+0.9%$3.50+109.0%N/A$289.29MN/A0.00N/ANews CoverageAMTXAemetis2.0098 of 5 stars$3.93+1.6%$12.95+229.5%-20.8%$195.48M$186.72M0.00160 Related Companies and Tools Related Companies MBII Alternatives LFVN Alternatives AVD Alternatives CGA Alternatives NAII Alternatives LXFR Alternatives ARQ Alternatives SDST Alternatives SLI Alternatives AMTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CBUS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cibus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cibus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
